Quick Answer
Anika Therapeutics, Inc. reported Total Assets of $190.27 million for the year ending 2025.
- Anika Therapeutics, Inc. showed a decrease of -6.2% in Total Assets from 2024 to 2025.
- This data is from Anika Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2011: $129.78 million | Q1 2012: $133.23 million | Q2 2012: $136.38 million | Q3 2012: $134.87 million | Q1 2013: $141.36 million | Q2 2013: $148.39 million | Q3 2013: $156.88 million | Q1 2014: $174.06 million | Q2 2014: $179.10 million | Q3 2014: $185.50 million | Q1 2015: $197.68 million | Q2 2015: $208.01 million | Q3 2015: $222.85 million | Q1 2016: $214.46 million | Q2 2016: $222.74 million | Q3 2016: $231.06 million | Q1 2017: $247.37 million | Q2 2017: $265.00 million | Q3 2017: $273.13 million | Q1 2018: $284.34 million | Q2 2018: $265.41 million | Q3 2018: $269.26 million | Q1 2019: $306.66 million | Q2 2019: $287.36 million | Q3 2019: $319.58 million | Q1 2020: $398.91 million | Q2 2020: $440.53 million | Q3 2020: $416.34 million | Q1 2021: $362.25 million | Q2 2021: $363.13 million | Q3 2021: $352.93 million | Q1 2022: $342.24 million | Q2 2022: $354.12 million | Q3 2022: $347.75 million | Q1 2023: $339.07 million | Q2 2023: $328.88 million | Q3 2023: $328.16 million | Q1 2024: $263.74 million | Q2 2024: $262.66 million | Q3 2024: $231.41 million | Q1 2025: $190.61 million | Q2 2025: $187.68 million | Q3 2025: $189.44 million.
- Over the full 16 years of available data (2010 to 2025), Anika Therapeutics, Inc.'s Total Assets has grown by 47.6%.
- Historical annual values: Fiscal year 2025: $190.27 million | Fiscal year 2024: $202.74 million | Fiscal year 2023: $270.63 million | Fiscal year 2022: $349.13 million | Fiscal year 2021: $347.54 million | Fiscal year 2020: $365.61 million | Fiscal year 2019: $330.71 million | Fiscal year 2018: $278.99 million | Fiscal year 2017: $282.62 million | Fiscal year 2016: $240.25 million | Fiscal year 2015: $235.75 million | Fiscal year 2014: $192.81 million | Fiscal year 2013: $156.04 million | Fiscal year 2012: $142.07 million | Fiscal year 2011: $132.84 million | Fiscal year 2010: $128.94 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: